CoChat

Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States

Open access
Stopeck, Alison, Rader, Michael, Henry, David, Danese, Mark, Halperin, Marc, Cong, Ze, Qian, Yi, Dansey, Roger, Chung, Karen · 2012 · Journal of Medical Economics
Cited by 64

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: With increasing healthcare resource constraints, it has become important to understand the incremental cost-effectiveness of new medicines. Subcutaneous denosumab is superior to intravenous zoledronic acid (ZA) for the prevention of skeletal-related events (SREs) in patients with advanced solid tumors and bone metastases. This study sought to determine the lifetime cost-effectiveness of denosumab vs ZA in this setting, from a US managed-care perspective. METHODS: A lifetime Markov model was developed, with relative rate reductions in SREs for denosumab vs ZA derived from three pivotal Phase 3 trials involving patients with castration-resistant prostate cancer (CRPC), breast cancer, and non-small-cell lung cancer (NSCLC), and bone metastases. The real-world SRE rates in ZA-treated patients were derived from a large commercial database. SRE and treatment administration quality-adjusted life year (QALY) decrements were estimated with time-trade-off studies. SRE costs were estimated from a nationally representative commercial claims database. Drug, drug administration, and renal monitoring costs were included. Costs and QALYs were discounted at 3% annually. One-way and probabilistic sensitivity analyses were conducted. RESULTS: Across tumor types, denosumab was associated with a reduced number of SREs, increased QALYs, and increased lifetime total costs vs ZA. The costs per QALY gained for denosumab vs ZA in CRPC, breast cancer, and NSCLC were $49,405, $78,915, and $67,931, respectively, commonly considered good value in the US. Costs per SRE avoided were $8567, $13,557, and $10,513, respectively. Results were sensitive to drug costs and SRE rates. LIMITATIONS: Differences in pain severity and analgesic use favoring denosumab over ZA were not captured. Mortality was extrapolated from fitted generalized gamma function beyond the trial duration. CONCLUSION: Denosumab is a cost-effective treatment option for the prevention of SREs in patients with advanced solid tumors and bone metastases compared to ZA. The overall value of denosumab is based on superior efficacy, favorable safety, and more efficient administration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3111/13696998.2012.675380

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 44

  1. 10.1634/theoncologist.9-90004-14 · DOI · Paper page
  2. Mundy GR, 2002, Nat Rev Cancer, 2, 584, 10.1038/nrc867 · DOI · Paper page
  3. Roodman GD, 2004, N Engl J Med, 350, 1655, 10.1056/NEJMra030831 · DOI · Paper page
  4. Coleman RE, 1997, Cancer, 80, 1588, 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G · DOI · Paper page
  5. Coleman RE, 2006, Clin Cancer Res, 12, 6243s, 10.1158/1078-0432.CCR-06-0931 · DOI · Paper page
  6. 10.1093/annonc/mdi122 · DOI · Paper page
  7. Pockett RD, 2010, Eur J Cancer Care (Engl), 19, 755, 10.1111/j.1365-2354.2009.01135.x · DOI
  8. Delea T, 2006, J Support Oncol, 4, 341
  9. Barlev A, 2010, J Manag Care Pharm, 16, 693, 10.18553/jmcp.2010.16.9.693 · DOI · Paper page
  10. 10.1002/cncr.23775 · DOI
  11. 10.1200/JCO.2005.05.116 · DOI · Paper page
  12. 10.1093/jnci/djh141 · DOI · Paper page
  13. Fizazi K, 2011, Lancet, 377, 813, 10.1016/S0140-6736(10)62344-6 · DOI · Paper page
  14. Stopeck AT, 2010, J Clin Oncol, 28, 5132, 10.1200/JCO.2010.29.7101 · DOI · Paper page
  15. Henry DH, 2011, J Clin Oncol, 29, 1125, 10.1200/JCO.2010.31.3304 · DOI · Paper page
  16. Lipton A, 2011, Ann Oncol, 21, viii380
  17. von Moos R, 2010, J Clin Oncol, 18
  18. Stopeck AT, 2010, J Clin Oncol, 28, 10.1200/JCO.2010.29.7101 · DOI · Paper page
  19. Fallowfield L, 2011, J Clin Oncol, 29
  20. Annemans L, 2010, Drug Dev Res, 71, 457, 10.1002/ddr.20420 · doi:10.1002/ddr.20420
  21. Coleman RE, 2011, Nat Rev Urol, 8, 296, 10.1038/nrurol.2011.63 · DOI
  22. 10.1200/JCO.2010.33.5596 · DOI
  23. Xie J, 2011, J Manag Care Pharm, 17, 621, 10.18553/jmcp.2011.17.8.621 · DOI
  24. Rader M, 2012, J Manag Care Pharm, 18, 74, 10.18553/jmcp.2012.18.1.74 · DOI
  25. Gold MR, 1996, Cost-effectiveness in health and medicine, 10.1093/oso/9780195108248.001.0001 · DOI · Paper page
  26. Botteman M, 2006, Ann Oncol, 17, 1072, 10.1093/annonc/mdl093 · DOI
  27. McKeage K, 2008, Pharmacoeconomics, 26, 251, 10.2165/00019053-200826030-00007 · DOI
  28. Saad F, 2002, Clin Prostate Cancer, 1, 145, 10.3816/CGC.2002.n.016 · DOI
  29. Matza LS, 2011, J Clin Oncol, 19
  30. Bell JM, 2011, Value Health, 14, A159, 10.1016/j.jval.2011.02.885 · DOI
  31. Sathiakumar N, 2011, Prostate Cancer Prostatic Dis, 14, 177, 10.1038/pcan.2011.7 · DOI · Paper page
  32. 10.1007/s005200100249 · DOI
  33. Oglesby A, 2009, Commun Oncol, 6, 494, 10.1016/S1548-5315(11)70357-6 · DOI
  34. Lage MJ, 2008, Am J Manag Care, 14, 317
  35. Brazier J, 1993, Qual Life Res, 2, 169, 10.1007/BF00435221 · DOI · Paper page
  36. Hinz A, 2006, Psychother Psychosom Med Psychol, 56, 42, 10.1055/s-2005-867061 · DOI
  37. Kaarlola A, 2004, Intensive Care Med, 30, 2245, 10.1007/s00134-004-2471-6 · DOI
  38. Stein K, 2005, Appl Health Econ Health Policy, 4, 219, 10.2165/00148365-200504040-00004 · DOI
  39. 10.1586/14737167.2.2.99 · DOI
  40. Brazier J, 2008, Pharmacoeconomics, 26, 769, 10.2165/00019053-200826090-00007 · DOI
  41. Chambers JD, 2010, Med Decis Making, 30, E14, 10.1177/0272989X10371134 · DOI
  42. Nadler E, 2006, Oncologist, 11, 90, 10.1634/theoncologist.11-2-90 · DOI · Paper page
  43. Lee CP, 2009, Value Health, 12, 80, 10.1111/j.1524-4733.2008.00401.x · DOI · Paper page
  44. 10.1097/01.ju.0000116777.94426.60 · DOI

Cited by

See all 64

Metadata

Authors
Stopeck, A., Rader, M., Henry, D., Danese, M., Halperin, M., Cong, Z., Qian, Y., Dansey, R., & Chung, K.
Venue
Journal of Medical Economics
Published
2012-03-27
Volume
15
Issue
4
Pages
712-723
ISSN
  • 1369-6998 (ISSN-L)
  • 1941-837X
OpenAlex
W2153087381
Cited by
64
References
3
FWCI
3.55
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. https://app.cochat.ai/papers/10.3111/13696998.2012.675380
The paper
Stopeck, A., Rader, M., Henry, D., Danese, M., Halperin, M., Cong, Z., Qian, Y., Dansey, R., & Chung, K. (2012). Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. Journal of Medical Economics. https://doi.org/10.3111/13696998.2012.675380

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.